Literature DB >> 18089752

CD134 and CXCR4 expression corresponds to feline immunodeficiency virus infection of lymphocytes, macrophages and dendritic cells.

F Reggeti1, C Ackerley2, D Bienzle1.   

Abstract

The lymphotropic lentiviruses feline immunodeficiency virus (FIV) and human immunodeficiency virus (HIV) enter cells by sequential interaction with primary receptors CD134 or CD4, respectively, and subsequently with chemokine receptors. The host-cell range for FIV is broader than that for HIV, but whether this is a function of receptor expression is unknown. Lack of reagents specific to feline molecules has limited detection and analysis of receptors and their interaction with viral components. Here, the expression of CD134 and CXCR4 on feline T and B lymphocytes, dendritic cells (DCs) and macrophages was examined and the kinetics of FIV replication were assessed. Quantification of CD134 mRNA by real-time PCR indicated expression in all leukocytes, with significantly more transcripts in CD4(+) lymphocytes than in other leukocytes. Antibodies against human CD134 bound inconsistently to feline leukocytes. CXCR4 was detected with antibody clone 12G5 on the surface of monocyte-derived cells only, but gene transcripts were present in all cells, with the highest copy number in lymphocytes. CXCR4 expression decreased and CD134 expression increased with cell activation in lymphocytes. A subtype B biological isolate of FIV infected DCs, macrophages and lymphocytes, with the highest replication in CD4(+) lymphocytes, whilst cloned FIV P14 infected all cells, but replicated less efficiently. Although viral replication was lower in DCs and macrophages than in lymphocytes, DCs expressed specific receptors and were infected productively with FIV, as indicated by viral ultrastructure and DNA detection. These results may implicate altered function of DCs in the induction of specific immunity against FIV.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18089752     DOI: 10.1099/vir.0.83161-0

Source DB:  PubMed          Journal:  J Gen Virol        ISSN: 0022-1317            Impact factor:   3.891


  8 in total

Review 1.  Feline immunodeficiency virus model for designing HIV/AIDS vaccines.

Authors:  Janet K Yamamoto; Missa P Sanou; Jeffrey R Abbott; James K Coleman
Journal:  Curr HIV Res       Date:  2010-01       Impact factor: 1.581

Review 2.  Utilizing the FIV model to understand dendritic cell dysfunction and the potential role of dendritic cell immunization in HIV infection.

Authors:  Tracy L Lehman; Kevin P O'Halloran; Edward A Hoover; Paul R Avery
Journal:  Vet Immunol Immunopathol       Date:  2009-10-14       Impact factor: 2.046

Review 3.  The molecular biology of feline immunodeficiency virus (FIV).

Authors:  Julia C Kenyon; Andrew M L Lever
Journal:  Viruses       Date:  2011-11-09       Impact factor: 5.048

Review 4.  Feline immunodeficiency virus in South America.

Authors:  Bruno M Teixeira; Mitika K Hagiwara; Juliano C M Cruz; Margaret J Hosie
Journal:  Viruses       Date:  2012-03-14       Impact factor: 5.818

Review 5.  Vaccine-associated enhanced disease in humans and animal models: Lessons and challenges for vaccine development.

Authors:  Julie Bigay; Roger Le Grand; Frédéric Martinon; Pauline Maisonnasse
Journal:  Front Microbiol       Date:  2022-08-10       Impact factor: 6.064

6.  Aberrant placental immune parameters in the feline immunodeficiency virus (FIV)-infected cat suggest virus-induced changes in T cell function.

Authors:  Lyndon Bart Chumbley; Crystal E Boudreaux; Karen S Coats
Journal:  Virol J       Date:  2013-07-19       Impact factor: 4.099

7.  Viral Reservoirs in Lymph Nodes of FIV-Infected Progressor and Long-Term Non-Progressor Cats during the Asymptomatic Phase.

Authors:  C D Eckstrand; C Hillman; A L Smith; E E Sparger; B G Murphy
Journal:  PLoS One       Date:  2016-01-07       Impact factor: 3.240

Review 8.  Vaccine-induced enhancement of viral infections.

Authors:  W Huisman; B E E Martina; G F Rimmelzwaan; R A Gruters; A D M E Osterhaus
Journal:  Vaccine       Date:  2008-11-18       Impact factor: 3.641

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.